1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)- has been researched along with Kidney Failure, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bashore, TM; Davidson, CJ; Freed, MI; Holcslaw, T; Miller, D; Rudnick, MR; Schwab, SJ; Shusterman, N; Szerlip, H; Thames, MD; Wang, A | 1 |
1 trial(s) available for 1h-indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1s,2r,3s)- and Kidney Failure, Chronic
| Article | Year |
|---|---|
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.
Topics: Aged; Contrast Media; Coronary Angiography; Creatinine; Endothelin Receptor Antagonists; Female; Humans; Hypotension; Indans; Injections, Intravenous; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Sodium Chloride; Time Factors | 2000 |